Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
OwnerKingston Mills, Peter Mcguirk +1inventors
InventorsKingston Mills, Peter Mcguirk, Brian Keogh
Life of this patent
Estimating the term…
Abstract
Filamentous haemagglutinin (FHA) or a derivative or mutant or fragment or variant or peptide thereof is useful in the prophylaxis and/or treatment of an immune-mediated disorder and/or an autoimmune disease. The FHA may include self or foreign antigens or peptides thereof.
Claims48
1-49. (canceled)
A pharmaceutical composition comprising substantially purified filamentous haemagglutinin (FHA) or derivative or mutant or fragment or variant or peptide thereof that is substantially endotoxin-free.
(canceled)
58-59. (canceled)
An immunomodulator comprising substantially purified FHA or derivative or mutant or fragment or variant or peptide thereof that is substantially endotoxin-free.
A recombinant FHA having immunomodulatory effects.
A vaccine comprising substantially purified FHA or derivative or mutant or fragment or variant or peptide thereof that is substantially endotoxin-free.
Antibodies to substantially purified FHA or derivative or mutant or fragment or variant or peptide thereof.
A method for preparing a substantially pure preparation of FHA comprising the steps of:
- dialysing a preparation of FHA to denature the protein and expose contaminating endotoxin, and
- removing residual contaminating endotoxin.
The method of 69 wherein the endotoxin is removed using a detergent.
A method for the prophylaxis and/or treatment of an immune-mediated disorder comprising the step of administering an agent comprising filamentous haemagglutinin (FHA) or a derivative or mutant or fragment or variant or peptide thereof that is substantially endotoxin-free.
(canceled)
84-87. (canceled)
90-94. (canceled)
97-100. (canceled)
(canceled)
104-107. (canceled)
Dependencies are inferred from the claim text.